Cargando…
Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants
OBJECTIVE: Duchenne muscular dystrophy (DMD) is characterised by progressive muscle weakness. It has recently been reported that single nucleotide polymorphisms (SNPs) located in the SPP1 and LTBP4 loci can account for some of the inter-individual variability observed in the clinical disease course....
Autores principales: | van den Bergen, Janneke C, Hiller, Monika, Böhringer, Stefan, Vijfhuizen, Linda, Ginjaar, Hendrika B, Chaouch, Amina, Bushby, Kate, Straub, Volker, Scoto, Mariacristina, Cirak, Sebahattin, Humbertclaude, Véronique, Claustres, Mireille, Scotton, Chiara, Passarelli, Chiara, Lochmüller, Hanns, Muntoni, Francesco, Tuffery-Giraud, Sylvie, Ferlini, Alessandra, Aartsma-Rus, Annemieke M, Verschuuren, Jan J G M, 't Hoen, Peter AC, Spitali, Pietro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602257/ https://www.ncbi.nlm.nih.gov/pubmed/25476005 http://dx.doi.org/10.1136/jnnp-2014-308409 |
Ejemplares similares
-
TCTEX1D1 is a genetic modifier of disease progression in Duchenne muscular dystrophy
por: Spitali, Pietro, et al.
Publicado: (2020) -
Whole-genome sequencing and the clinician: a tale of two cities
por: Foley, A Reghan, et al.
Publicado: (2014) -
The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials
por: Ricotti, Valeria, et al.
Publicado: (2016) -
Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials
por: Diaz-Manera, Jordi, et al.
Publicado: (2018) -
Dystromirs as Serum Biomarkers for Monitoring the Disease Severity in Duchenne Muscular Dystrophy
por: Zaharieva, Irina T., et al.
Publicado: (2013)